Plain-English translation of NCT06163430 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see if it can help people with chronic myeloid leukemia (a type of blood cancer) whose disease has not responded well to previous treatments. works differently than older medications by targeting a specific part of the cancer cells that cause the disease. The study will look at how safe the medication is, how your body handles it, and whether it actually helps control the cancer.
Many people with chronic myeloid leukemia develop resistance to standard treatments or cannot tolerate their side effects. This medication was designed to work in a new way that might help people who have exhausted other options.
You likely qualify if…
You likely don't qualify if…
You would take the medication once a day by mouth in 28-day cycles. During the first cycle, you would have frequent visits to the trial center (on days 1, 2, 8, and 15). After that, you would visit on the first day of cycles 2 through 7, then every three cycles after that. The study will monitor you closely with blood tests and exams to check how well the medication is working and whether you are having any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States